• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Adv . One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk

tetano

Editor, Senior Moderator
Sci Adv


. 2022 Apr 15;8(15):eabm5016.
doi: 10.1126/sciadv.abm5016. Epub 2022 Apr 15.
One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk


Christine Klein[SUP] 1 [/SUP], Max Borsche[SUP] 1 [/SUP], Alexander Balck[SUP] 1 2 [/SUP], Bandik Föh[SUP] 3 4 [/SUP], Johann Rahmöller[SUP] 3 5 [/SUP], Elke Peters[SUP] 6 [/SUP], Jan Knickmann[SUP] 7 [/SUP], Miranda Lane[SUP] 7 [/SUP], Eva-Juliane Vollstedt[SUP] 1 [/SUP], Susanne A Elsner[SUP] 6 [/SUP], Nadja Käding[SUP] 8 [/SUP], Susanne Hauswaldt[SUP] 8 [/SUP], Tanja Lange[SUP] 9 [/SUP], Jennifer E Hundt[SUP] 10 [/SUP], Selina Lehrian[SUP] 3 [/SUP], Julia Giese[SUP] 3 [/SUP], Alexander Mischnik[SUP] 11 [/SUP], Stefan Niemann[SUP] 12 13 [/SUP], Florian Maurer[SUP] 12 [/SUP], Susanne Homolka[SUP] 12 [/SUP], Laura Paulowski[SUP] 12 [/SUP], Jan Kramer[SUP] 7 14 [/SUP], Christoph Twesten[SUP] 15 [/SUP], Christian Sina[SUP] 3 [/SUP], Gabriele Gillessen-Kaesbach[SUP] 16 [/SUP], Hauke Busch[SUP] 10 [/SUP], Marc Ehlers[SUP] 3 [/SUP], Stefan Taube[SUP] 7 [/SUP], Jan Rupp[SUP] 8 [/SUP], Alexander Katalinic[SUP] 6 [/SUP]



Affiliations

Abstract

With newly rising coronavirus disease 2019 (COVID-19) cases, important data gaps remain on (i) long-term dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates in fixed cohorts (ii) identification of risk factors, and (iii) establishment of effective surveillance strategies. By polymerase chain reaction and antibody testing of 1% of the local population and >90,000 app-based datasets, the present study surveilled a catchment area of 300,000 inhabitants from March 2020 to February 2021. Cohort (56% female; mean age, 45.6 years) retention was 75 to 98%. Increased risk for seropositivity was detected in several high-exposure groups, especially nurses. Unreported infections dropped from 92 to 29% during the study. "Contact to COVID-19-affected" was the strongest risk factor, whereas public transportation, having children in school, or tourism did not affect infection rates. With the first SARS-CoV-2 cohort study, we provide a transferable model for effective surveillance, enabling monitoring of reinfection rates and increased preparedness for future pandemics.
 
Back
Top Bottom